The obesity pipeline is moving faster than the evidence can be absorbed. A new class of amylin-based agents — investigational therapies now advancing through phase 2 and phase 3 trials with several studied both on their own and in combination …
Obesity looks like one diagnosis but behaves like many. Two patients with the same body mass index (BMI) can respond very differently to the same medication, and as the treatment armamentarium expands, from today’s incretins to the amylin-based and combination …
Anti-vascular endothelial growth factor (anti-VEGF) therapy transformed the management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), but it has not solved either disease. Roughly 40% to 60% of patients with DME and 40% to 50% with …
Anti-vascular endothelial growth factor (anti-VEGF) therapy transformed the management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), but it has not solved either disease. Roughly 40% to 60% of patients with DME and 40% to 50% with …
The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has historically been anchored by surgery, radiation therapy, and chemoradiation. Care for this complex disease requires navigating diverse tumor biology, multiple sites of origin, and significant …
Obesity care is moving quickly past the one-drug, one-pathway era. Current therapies have reshaped what treatment can achieve, yet responses vary widely and not every patient tolerates or responds to them, leaving clinicians searching for the next complementary mechanism. Amylin …
The idiopathic inflammatory myopathy (IIM) landscape is evolving rapidly, transforming how clinicians recognize disease, assess risk, and select treatment, but translating these advances into everyday practice remains a challenge. As biomarkers and myositis-specific autoantibodies enable increasingly precise subtype classification, clinicians …
Effective pain management is more complex than ever. As opioid prescribing guidance continues to evolve, clinicians must stay current with the latest evidence to deliver safe and patient-centered care. The FDA Opioid Analgesic REMS Education Blueprint and the 2022 CDC …
More than 40% of U.S. adults now live with obesity, and incretin-based therapies have transformed what treatment can achieve. Yet the same clinical experience that produced those gains has exposed their limits: response varies widely from patient to patient, persistence …